WO2010034490A1 - Uroactivine peptidique en tant qu'activateur de l'enzyme urokinase - Google Patents

Uroactivine peptidique en tant qu'activateur de l'enzyme urokinase Download PDF

Info

Publication number
WO2010034490A1
WO2010034490A1 PCT/EP2009/006899 EP2009006899W WO2010034490A1 WO 2010034490 A1 WO2010034490 A1 WO 2010034490A1 EP 2009006899 W EP2009006899 W EP 2009006899W WO 2010034490 A1 WO2010034490 A1 WO 2010034490A1
Authority
WO
WIPO (PCT)
Prior art keywords
uroaktivin
amino acid
acid sequence
peptide
peptidomimetics
Prior art date
Application number
PCT/EP2009/006899
Other languages
English (en)
Inventor
Natasa Obermajer
Bojan Doljak
Janko Kos
Original Assignee
Univerza V Ljubljani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univerza V Ljubljani filed Critical Univerza V Ljubljani
Publication of WO2010034490A1 publication Critical patent/WO2010034490A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Au cours des études intensives qui ont amené à la présente invention, les inventeurs ont découvert que l'uroactivine peptidique avec la séquence d'acides aminés SEQ ID NO : 1 se lie à et augmente l'activité d'un activateur de plasminogène du type urokinase (urokinase, uPA) et d'un activateur de plasminogène du type tissu (tPA). La présente invention fournit en premier lieu la séquence d'acides aminés de l'uroactivine peptidique - SEQ ID NO : 1. La présente invention fournit également l'utilisation de l'uroactivine peptidique pour une thérapie plus efficace de maladies ou d'états pour lesquels des médicaments thrombolytiques sont indiqués. Ces états sont spécifiquement les suivants : thrombose coronaire aiguë (infarctus du myocarde aigu), infarctus cérébral ischémique aigu, thromboembolie de poumon aiguë, thrombose veineuse profonde, thromboembolie artérielle aiguë, thrombose artérielle aiguë. L'uroactivine peptidique peut également être utilisé pour assurer la perméabilité de canules artérioveineuses et de cathéters intraveineux.
PCT/EP2009/006899 2008-09-25 2009-09-24 Uroactivine peptidique en tant qu'activateur de l'enzyme urokinase WO2010034490A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200800224A SI22865A (sl) 2008-09-25 2008-09-25 Peptid uroaktivin kot aktivator encima urokinaze
SIP-200800224 2008-09-25

Publications (1)

Publication Number Publication Date
WO2010034490A1 true WO2010034490A1 (fr) 2010-04-01

Family

ID=41227264

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/006899 WO2010034490A1 (fr) 2008-09-25 2009-09-24 Uroactivine peptidique en tant qu'activateur de l'enzyme urokinase

Country Status (2)

Country Link
SI (1) SI22865A (fr)
WO (1) WO2010034490A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2768852A4 (fr) * 2011-10-19 2015-05-13 Theratechnologies Inc Composés peptidiques dérivés de la mélanotransferrine et leurs utilisations
US11033611B2 (en) 2013-11-04 2021-06-15 Board Of Regents, The University Of Texas System Compositions and methods for administration of an enzyme to a subject's airway
WO2022117724A1 (fr) 2020-12-04 2022-06-09 Univerza V Ljubljani Inhibiteurs de cystéine protéase à base de 8-hydroxyquinoléine destinés à être utilisés dans la prévention et/ou le traitement d'une maladie à coronavirus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DOLJAK B ET AL: "Monoclonal antibody to cytokeratin VKIALEVEIATY sequence motif reduces plasminogen activation in breast tumour cells", CANCER LETTERS, NEW YORK, NY, US, vol. 267, no. 1, 18 August 2008 (2008-08-18), pages 75 - 84, XP022797044, ISSN: 0304-3835, [retrieved on 20080422] *
KOS J ET AL: "Inactivation of harmful tumour-associated proteolysis by nanoparticulate system", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 381, no. 2, 3 November 2009 (2009-11-03), pages 106 - 112, XP026643514, ISSN: 0378-5173, [retrieved on 20090505] *
KRALOVICH KRISTEN R ET AL: "Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18", JOURNAL OF PROTEIN CHEMISTRY, vol. 17, no. 8, November 1998 (1998-11-01), pages 845 - 854, XP002556192, ISSN: 0277-8033 *
OBERMAJER NATASA ET AL: "Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.", MOLECULAR CANCER 2009, vol. 8, 2009, pages 88, XP002556193, ISSN: 1476-4598 *
TURK BORIS: "Targeting proteases: successes, failures and future prospects.", NATURE REVIEWS. DRUG DISCOVERY SEP 2006, vol. 5, no. 9, September 2006 (2006-09-01), pages 785 - 799, XP002556191, ISSN: 1474-1776 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2768852A4 (fr) * 2011-10-19 2015-05-13 Theratechnologies Inc Composés peptidiques dérivés de la mélanotransferrine et leurs utilisations
US9334314B2 (en) 2011-10-19 2016-05-10 Theratechnologies Inc. Peptide compounds derived from melanotransferrin and uses thereof
US11033611B2 (en) 2013-11-04 2021-06-15 Board Of Regents, The University Of Texas System Compositions and methods for administration of an enzyme to a subject's airway
WO2022117724A1 (fr) 2020-12-04 2022-06-09 Univerza V Ljubljani Inhibiteurs de cystéine protéase à base de 8-hydroxyquinoléine destinés à être utilisés dans la prévention et/ou le traitement d'une maladie à coronavirus

Also Published As

Publication number Publication date
SI22865A (sl) 2010-03-31

Similar Documents

Publication Publication Date Title
Nagashima et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model
Redlitz et al. Plasma carboxypeptidases as regulators of the plasminogen system.
Kaplan et al. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway
Joseph et al. Formation of bradykinin: a major contributor to the innate inflammatory response
Vali et al. Localization of the binding site on fibrin for the secondary binding site of thrombin
Gils et al. Modulation of TAFI function through different pathways–implications for the development of TAFI inhibitors
US9834614B2 (en) Method of increasing plasmin activity through antiplasmin conversion
Flight et al. Comparison of textilinin-1 with aprotinin as serine protease inhibitors and as antifibrinolytic agents
Da Silva et al. Anti-platelet effect of cumanastatin 1, a disintegrin isolated from venom of South American Crotalus rattlesnake
Dewerchin et al. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo
KR20060133031A (ko) 트롬빈 유도체 및 그것을 포함하는 의약 조성물
Mattsson et al. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro
WO2010034490A1 (fr) Uroactivine peptidique en tant qu'activateur de l'enzyme urokinase
Weisel et al. Mechanisms of fibrinolysis and basic principles of management
Nieuwenhuizen Fibrinogen and its specific sites for modulation of t-PA induced fibrinolysis
Prentice et al. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products
Conard et al. Theoretic and practical considerations on laboratory monitoring of thrombolytic therapy
Mutch Regulation of fibrinolysis by platelets
Guimarães et al. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models
Sheffield et al. A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models
De Caterina et al. Cellular effects of thrombin: pharmacology of the receptor (s) in various cell types and possible development of receptor antagonists
Mahmoud-Alexandroni et al. Sensitive and direct assays for functionally active plasminogen activators (tissue-type and urokinase-type) in plasma
Ren et al. Study on the activity of recombinant mutant tissue-type plasminogen activator fused with the C-terminal fragment of hirudin
Rånby et al. Control of t-PA-mediated fibrinolysis
Blomback Fibrinogen and fibrin formation and its role in fibrinolysis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09778696

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09778696

Country of ref document: EP

Kind code of ref document: A1